Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

计划入组 93 人 · 首次发布于 2017 年 10 月 6 日

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

计划入组 63 人 · 首次发布于 2018 年 7 月 9 日

MuSK Myasthenia 1000 Study

计划入组 1,000 人 · 首次发布于 2024 年 2 月 14 日

MuSK-CAART

Moschus berezovskii musk sac resin

DAS-MG, Inc

Mistras Group

United States

MaYingLong Pharmaceutical Group CO.,LTD．

China

NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment

GlycoEra Appoints Petra Duda as Chief Medical Officer to Lead Precision Protein Degrader Pipeline

Fulvestrant Shows Overall Survival Benefit Over Anastrozole in First-Line Advanced Breast Cancer